Genetic variants, neurocognitive outcomes, and functional neuroimaging in survivors of childhood acute lymphoblastic leukemia

Abstract Background Genetic predispositions may modulate risk for developing neurocognitive late effects in childhood acute lymphoblastic leukemia (ALL) survivors. Methods Long-term ALL survivors (n = 212; mean = 14.3 [SD = 4.77] years; 49% female) treated with chemotherapy completed neurocognitive testing and task-based functional neuroimaging. Based on previous work from our team, genetic variants related to the folate pathway, glucocorticoid regulation, drug metabolism, oxidative stress, and attention were included as predictors of neurocognitive performance, using multivariable models adjusted for age, race, and sex. Subsequent analyses evaluated the impact of these variants on task-based functional neuroimaging. Statistical tests were 2-sided. Results Survivors exhibited higher rates of impaired attention (20.8%), motor skills (42.2%), visuo-spatial memory (49.3%-58.3%), processing speed (20.1%), and executive function (24.3%-26.1%) relative to population norms (10%; P < .001). Genetic variants implicated in attention deficit phenotypes predicted impaired attention span (synaptosome associated protein 25, F(2,172) = 4.07, P = .019) and motor skills (monoamine oxidase A, F(2,125) = 5.25, P = .007). Visuo-spatial memory and processing speed varied as a function of genetic variants in the folate pathway (methylenetetrahydrofolate reductase [MTHFRrs1801133], F(2,165) = 3.48, P = .033; methylenetetrahydrofolate dehydrogenase 1 [MTHFD1rs2236225], F(2,135) = 3.8, P = .025; respectively). Executive function performance was modulated by genetic variants in the folate pathway (MTHFD1rs2236225, F(2,158) = 3.95, P = .021; MTHFD1rs1950902, F(2,154) = 5.55, P = .005) and glucocorticoid regulation (vitamin D receptor, F(2,158) = 3.29, P = .039; FKBP prolyl isomerase 5, F(2,154) = 5.6, P = .005). Additionally, MTHFD1rs2236225 and FKBP prolyl isomerase 5 were associated with altered brain function during attention and working memory (P < .05; family wise error corrected). Conclusions Results extend previous findings of genetic risk of neurocognitive impairment following ALL therapy and highlight the importance of examining genetic modulators in relation to neurocognitive deficits.

[1]  Y. T. Cheung,et al.  Cognitive Impairment in Survivors of Pediatric Acute Lymphoblastic Leukemia Treated With Chemotherapy Only. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Armstrong,et al.  Sex-specific associations between chemotherapy, chronic conditions and neurocognitive impairment in ALL survivors: A report from the Childhood Cancer Survivor Study. , 2020, Journal of the National Cancer Institute.

[3]  Carmen L. Wilson,et al.  A Novel Locus Predicts Spermatogenic Recovery among Childhood Cancer Survivors Exposed to Alkylating Agents , 2020, Cancer Research.

[4]  L. Lagae,et al.  Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review , 2019, Neuropsychology Review.

[5]  D. Michaelson,et al.  ApoE4: an emerging therapeutic target for Alzheimer’s disease , 2019, BMC Medicine.

[6]  Y. T. Cheung,et al.  Brain Network Connectivity and Executive Function in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia , 2018, Brain Connect..

[7]  S. Pollak,et al.  Early life stress, FK506 binding protein 5 gene (FKBP5) methylation, and inhibition-related prefrontal function: A prospective longitudinal study , 2017, Development and Psychopathology.

[8]  K. Felmingham,et al.  Association of FKBP5 polymorphisms and resting-state activity in a frontotemporal–parietal network , 2016, Translational psychiatry.

[9]  Y. T. Cheung,et al.  Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Basso,et al.  Verbal Fluency: Language or Executive Function Measure? , 2016, Applied neuropsychology. Adult.

[11]  M. Sprangers,et al.  Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. , 2015, The Lancet. Oncology.

[12]  Y. T. Cheung,et al.  Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review , 2015, Neuroscience & Biobehavioral Reviews.

[13]  Traci M. Blonquist,et al.  Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Weksberg,et al.  Neurocognitive Late Effects of Chemotherapy in Survivors of Acute Lymphoblastic Leukemia: Focus on Methotrexate. , 2015, Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent.

[15]  J. Neglia,et al.  The contribution of neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia , 2014, Psycho-oncology.

[16]  John O. Willis,et al.  Wechsler Abbreviated Scale of Intelligence , 2014 .

[17]  C. Pui,et al.  Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Howard J. Rosen,et al.  NIH EXAMINER: Conceptualization and Development of an Executive Function Battery , 2013, Journal of the International Neuropsychological Society.

[19]  Cheng Cheng,et al.  Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Kanyakumarika Sarkar,et al.  Role of SNAP25 Explored in Eastern Indian Attention Deficit Hyperactivity Disorder Probands , 2012, Neurochemical Research.

[21]  K. Krull,et al.  Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy , 2011, Pediatric blood & cancer.

[22]  G. Armstrong,et al.  Physical, Mental, and Neurocognitive Status and Employment Outcomes in the Childhood Cancer Survivor Study Cohort , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[23]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Cools,et al.  The Human Basal Ganglia Modulate Frontal-Posterior Connectivity during Attention Shifting , 2010, The Journal of Neuroscience.

[25]  E. Binder.  The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders , 2009, Psychoneuroendocrinology.

[26]  H. Bergman,et al.  The dynamics of dopamine in control of motor behavior , 2009, Current Opinion in Neurobiology.

[27]  D. Forero,et al.  Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: a meta-analysis of 8 common variants. , 2009, Journal of psychiatry & neuroscience : JPN.

[28]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[29]  A. Raine.  From Genes to Brain to Antisocial Behavior , 2008 .

[30]  Yufeng Wang,et al.  Monoamine oxidase A gene polymorphism predicts adolescent outcome of attention‐deficit/hyperactivity disorder , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[31]  Jun Soo Kwon,et al.  Clinical and empirical applications of the Rey–Osterrieth Complex Figure Test , 2006, Nature Protocols.

[32]  W. Roberts,et al.  The SNAP25 gene as a susceptibility gene contributing to attention-deficit hyperactivity disorder , 2005, Molecular Psychiatry.

[33]  Edith Kaplan,et al.  Reliability and validity of the Delis-Kaplan Executive Function System: An update , 2004, Journal of the International Neuropsychological Society.

[34]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[35]  W. Roberts,et al.  Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder , 2000, Molecular Psychiatry.

[36]  Allan L. Reiss,et al.  Basal Ganglia Volumes in Children With Attention-Deficit Hyperactivity Disorder , 1996, Journal of child neurology.

[37]  O. Selnes.  A Compendium of Neuropsychological Tests , 1991, Neurology.

[38]  G. Chelune,et al.  Developmental norms for the Wisconsin Card Sorting test. , 1986, Journal of clinical and experimental neuropsychology.

[39]  R. Evans,et al.  Primary structure and expression of a functional human glucocorticoid receptor cDNA , 1985, Nature.

[40]  Grote Kruisstraat.  What is the evidence of impaired motor skills and motor control among children with attention deficit hyperactivity disorder (ADHD)? Systematic review of the literature , 2015 .

[41]  M. Schoemaker,et al.  What is the evidence of impaired motor skills and motor control among children with attention deficit hyperactivity disorder (ADHD)? Systematic review of the literature. , 2015, Research in developmental disabilities.

[42]  K. Krull,et al.  Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. , 2008, The Journal of pediatrics.

[43]  J. Downing,et al.  Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.

[44]  M. Owen,et al.  Association analysis of monoamine oxidase A and attention deficit hyperactivity disorder , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[45]  L. Ries,et al.  Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .

[46]  J. Shih,et al.  MAO-A and -B gene knock-out mice exhibit distinctly different behavior. , 1999, Neurobiology.